207235-80-1

Upstream product

• 148747-76-6 [5-[(benzyloxycarbonyl)amino]-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl]acetic acid 
• 207235-68-5 2-amino-1-hydroxy-1-[5-(methoxy-carbonyl)benzoxazol-2-yl]-3-phenylpropane 
• 207235-69-6 2-benzyloxycarbonylamino-1-hydroxy-1-[5-(methoxycarbonyl)benzoxazol-2-yl]-3-phenylpropane 
• 66413-45-4 3-(benzyloxycarbonyl)amino-2-hydroxy-4-phenylbutanenitrile 
• 536-25-4 methyl 3-amino-4-hydroxybenzoate 
• 59830-60-3 N-benzyloxycarbonyl-2-amino-3-phenylpropionaldehyde 

Downstream Products

• 1026915-44-5 [1-{[1-benzyl-2-(5-diethylcarbamoyl-benzooxazol-2-yl)-2-oxo-ethylcarbamoyl]-methyl}-2-(4-fluoro-phenyl)-6-oxo-1,6-dihydro-pyrimidin-5-yl]-carbamic acid benzyl ester 
• 207235-86-7 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-[[5-(ethylaminocarbonyl)benzoxazol-2-yl]hydroxymethyl]-2-phenylethyl]acetamide 
• 207235-05-0 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-[[5-(ethylaminocarbonyl)benzoxazol-2-yl]carbonyl]-2-phenylethyl]acetamide 
• 339209-09-5 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-[(5-carbamoylbenzoxazol-2-yl)hydroxymethyl]-2-phenylethyl]acetamide 
• 339209-12-0 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-[(5-carbamoylbenzoxazol-2-yl)carbonyl]-2-phenylethyl]acetamide 
• 207234-98-8 2-[5-amino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-[[5-(methoxy-carbonyl)benzoxazol-2-yl]carbonyl]-2-phenylethyl]acetamide 
• 207235-85-6 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-[(5-carboxylbenzoxazol-2-yl)hydroxymethyl]-2-phenylethyl]acetamide 
• 207234-97-7 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-[[5-(methoxycarbonyl)benzoxazol-2-yl]carbonyl]-2-phenylethyl]acetamide 

Relevant academic research and scientific papers

IgE antibody production inhibitors and autoimmune diseases inhibitors

The present invention relates to an IgE antibody production inhibitor and an autoimmune disease suppressant containing a heterocyclic amide compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an activ

Synthesis, structure - Activity relationships, and pharmacokinetic profiles of nonpeptidic α-keto heterocycles as novel inhibitors of human chymase

We designed nonpeptidic chymase inhibitors based on the structure of a peptidic compound (1) and demonstrated that the combination of a pyrimidinone skeleton as a P3-P2 scaffold and heterocycles as P1 carbonyl-activating g